Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice.
暂无分享,去创建一个
L. Mucke | E. Masliah | T. Wyss-Coray | Manuel Buttini | Yadong Huang | J. Palop | Shengjun Chang | Carol Lin | Gui-qiu Yu | Aubrey Bernardo | Carol A. Lin
[1] Guojun Bu,et al. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.
[2] D. Geschwind,et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease , 2009, Nature Medicine.
[3] D. Holtzman,et al. ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.
[4] Brian Spencer,et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.
[5] Yadong Huang,et al. Intron-3 Retention/Splicing Controls Neuronal Expression of Apolipoprotein E in the CNS , 2008, The Journal of Neuroscience.
[6] E. Masliah,et al. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat , 2007, Experimental Neurology.
[7] J. Kelsoe,et al. Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice , 2007, Genes, brain, and behavior.
[8] Yadong Huang. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. , 2006, Current opinion in drug discovery & development.
[9] M. Christiansen,et al. The association between apolipoprotein E and multiple sclerosis , 2006, European journal of neurology.
[10] David Walker,et al. Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus , 2006, The Journal of Neuroscience.
[11] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[12] P. Deyn,et al. Dose dependent effect of APOE ɛ4 on behavioral symptoms in frontal lobe dementia , 2006, Neurobiology of Aging.
[13] R. Mahley,et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[14] E. Masliah,et al. β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[15] J. Haines,et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease , 2004, Neurology.
[16] Tony Wyss-Coray,et al. Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.
[17] R. Mahley,et al. Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells , 2004, Journal of Biological Chemistry.
[18] L. Mucke,et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] L. Mucke,et al. Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.
[20] D. Holtzman,et al. Apolipoprotein E, amyloid, and Alzheimer disease. , 2002, Molecular interventions.
[21] L. Mucke,et al. Androgens Protect against Apolipoprotein E4-Induced Cognitive Deficits , 2002, The Journal of Neuroscience.
[22] D. Holtzman,et al. Behavioral Phenotyping of GFAP-ApoE3 and -ApoE4 Transgenic Mice: ApoE4 Mice Show Profound Working Memory Impairments in the Absence of Alzheimer's-like Neuropathology , 2001, Experimental Neurology.
[23] R. Mahley,et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Bedlack,et al. Apolipoprotein E and neuromuscular disease: a critical review of the literature. , 2000, Archives of neurology.
[26] Raja Parasuraman,et al. Genetics and visual attention: Selective deficits in healthy adult carriers of the ɛ4 allele of the apolipoprotein E gene , 2000 .
[27] A. Fagan,et al. No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo , 2000, The European journal of neuroscience.
[28] A. Fagan,et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model , 2000, Annals of neurology.
[29] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[30] L. Mucke,et al. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease , 2000, Neuroscience.
[31] L. Mucke,et al. Alzheimer's disease: Apolipoprotein E and cognitive performance , 2000, Nature.
[32] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Roses,et al. Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress , 1999, Neurobiology of Disease.
[34] W. März,et al. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions , 1999, Acta Neuropathologica.
[35] Matthias Orth,et al. Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.
[36] R. Mahley,et al. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.
[37] J. D. Smith,et al. Human apolipoprotein E allele-specific brain expressing transgenic mice , 1998, Neurobiology of Aging.
[38] L. Mucke,et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[40] G. Murray,et al. Association of apolipoprotein E polymorphism with outcome after head injury , 1997, The Lancet.
[41] J. Olney,et al. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. , 1997, Archives of neurology.
[42] O. Steward,et al. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[43] A. Hofman,et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. , 1997, JAMA.
[44] A. Roses,et al. Neurodegeneration in the Central Nervous System of apoE-Deficient Mice , 1995, Experimental Neurology.
[45] R. Mantegna,et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[46] L. Mucke,et al. Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: In vivo comparison of distinct GFAP‐lacZ transgenes , 1995, Glia.
[47] J. Olney,et al. Excitotoxicity and the NMDA receptor - still lethal after eight years , 1995, Trends in Neurosciences.
[48] M. Pericak-Vance,et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Olney. Excitatory transmitter neurotoxicity , 1994, Neurobiology of Aging.
[50] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[51] E. Masliah,et al. Spectrum of human immunodeficiency virus–associated neocortical damage , 1992, Annals of neurology.
[52] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[53] E. Shooter,et al. Expression of apolipoprotein E during nerve degeneration and regeneration. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[55] L. Mucke,et al. Apolipoprotein E , 2007, Journal of Molecular Neuroscience.
[56] A D Roses,et al. Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.
[57] J. Breslow,et al. Human apolipoprotein E isoprotein subclasses are genetically determined. , 1981, American journal of human genetics.